Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 5(1A).

  • 2016-03
  • Microbes and Infection 18(3)
    • A. T. Vieira
    • V. Rocha
    • L. Tavares
    • Cristiana C Garcia
    • M. Teixeira
    • S. Oliveira
    • G. Cassali
    • C. Gamba
    • F. Martins
    • J. Nicoli

Abstract

Klebsiella pneumoniae (Kp) a common cause of pneumonia leads to intense lung injury and mortality that are correlated with infective exacerbations. Probiotics are a class of microorganisms that have immunomodulatory effects to benefit health. We investigated whether the probiotic Bifidobacterium longum 5(1A) induces protection in mice against lung infection induced by Kp and the potential involved mechanisms. Kp infection induced secretion of pro-inflammatory cytokines, neutrophil recruitment, significant bacterial load in the lung and 50% lethality. However, treatment with live B. longum 5(1A) induced faster resolution of inflammation associated with an increased production of IL-10, decreased lung damage with significantly reduction of bacterial burden that contributed to rescue 100% of mice from death. We found that these effects could be attributed, at least in part, to activation of the Toll-like receptor (TLR) adapter protein Mal, since B. longum 5(1A) treatment in Mal-deficient infected mice did not show the protection observed in wild type infected mice. Thus, we propose that live B. longum 5(1A) activates TLR-signaling pathway that results in ROS production and protects the host against pneumonia-induced death by finely tuning the inflammatory response and contributing to faster return to lung homeostasis.

Keywords: Bifidobacterium longum 5(1A); Inflammation; Klebsiella pneumoniae; Mal/TIRAP; Microbiota; Probiotic.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum KABP-042Increased IL-10 ProductionBeneficial
Large
Bifidobacterium longum KABP-042Reduced Bacterial Load in LungsBeneficial
Large
Bifidobacterium longum KABP-042Reduced Lung DamageBeneficial
Large
Bifidobacterium longum KABP-042Reduced MortalityBeneficial
Large
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.